Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Implementation of Genetic Testing in Prostate Cancer: A Real-World Survey of Outpatient Urologists in Germany (PRO-GEN).

Cancers·2026

Same author

[Androgen deprivation with definitive radiotherapy for localized prostate cancer: what is the optimal treatment duration?]

Urologie (Heidelberg, Germany)·2026

Same author

Micro-ultrasound as an alternative to MRI in prostate cancer biopsy: Correlation with prostatectomy findings.

Urologic oncology·2026

Same author

Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumors.

Frontiers in oncology·2026

Same author

Structured Feedback Tools in Surgical Training: Results of the Endo-Workshop of the German Society of Residents in Urology 2024.

Urologia internationalis·2026

Same author

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.

Clinical genitourinary cancer·2026

Search research articles

Related Experiment Video

Updated: Jul 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Precision oncology options in urological cancers].

Antonia Franz¹, Henning Plage¹, Annika Fendler¹

¹Klinik für Urologie, Charité - Universitätsmedizin Berlin, Charité Platz 1, 10117, Berlin, Deutschland.

Urologie (Heidelberg, Germany)

|June 9, 2023

Summary

Targeted therapies like FGFR and PARP inhibitors are revolutionizing uro-oncology. Molecular diagnostics guide personalized treatment for prostate, urothelial, and renal cell cancers, improving patient outcomes.

Keywords:

FGFR PARP Prostate cancer Sequencing Targets

More Related Videos

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Experiment Videos

Last Updated: Jul 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Area of Science:

Uro-oncology
Molecular genetics
Precision medicine

Context:

Molecular genetic advancements have identified new therapeutic targets for urological tumors.
Tumor sequencing enables individualized treatment decisions in precision oncology.
This review focuses on prostate cancer, urothelial carcinoma, and renal cell carcinoma.

Purpose:

To provide an overview of the latest targeted tumor therapies for urological malignancies.
To discuss current studies and promising drug targets in uro-oncology.
To highlight the importance of molecular diagnostics in personalized medicine.

Summary:

FGFR-inhibitors show high response rates in metastatic urothelial carcinoma with specific FGFR alterations.
PARP-inhibitors are effective in metastatic prostate cancer, especially in patients with BRCA mutations.
Ongoing research explores PI3K/AKT/mTOR and VEGF pathways, and HIF-2a inhibitors for renal cell carcinoma.

Impact:

Targeted therapies are transforming uro-oncological treatment paradigms.
Precision medicine, guided by molecular diagnostics, optimizes therapy selection for specific patient subgroups.
These advancements offer new hope and improved outcomes for patients with urological cancers.